If dual antibody therapy can eradicate some HER2-positive breast cancers in less than 2 weeks, a similar approach using a letrozole and dual anti-HER2 therapy from initial biopsy may improve selection of patients who can avoid chemotherapy. Here, ERBB2 is linked to breast cancer.